Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

KUEMMERLE-DESCHNER, Jasmin; HACHULLA, E.; CARTWRIGHT, R.; Hawkins, P.; TRAN, T.; Bader-Meunier, B.; HOYER, J.; GATTORNO, M.; Gül, AHMET; SMITH, J.; LESLIE, K.; JIMENEZ, S.; MORELL-DUBOIS, S.; DAVIS, N.; PATEL, N.; WIDMER, A.; PREISS, R.; Lachmann, H.

doi:10.1136/ard.2011.152728

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

KUEMMERLE-DESCHNER J. B., HACHULLA E., CARTWRIGHT R., Hawkins P. N., TRAN T. A., Bader-Meunier B., ...Daha Fazla

ANNALS OF THE RHEUMATIC DISEASES, cilt.70, sa.12, ss.2095-2102, 2011 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 70 Sayı: 12
Basım Tarihi: 2011
Doi Numarası: 10.1136/ard.2011.152728
Dergi Adı: ANNALS OF THE RHEUMATIC DISEASES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2095-2102
İstanbul Üniversitesi Adresli: Evet

Özet

Objective Longer-term effects of prolonged selective interleukin-1 beta blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date.